Abiopharma

We are a global biotech company working to unlock the potential of cell and gene
therapies ("CGTs") in an affordable and accessible format. CGTs can be centered on
autologous (using the patients own cells) or allogenic (using master banked donor cells)
and are part of a class of medicines referred to as advanced therapy medicinal products
("ATMPs"). We are mostly focused on autologous therapies that can be manufactured
under processes and systems that are developed for each therapy using a closed and
automated approach that is validated for compliant production near the patient for
treatment of the patient at the point of care ("POCare"). This approach has the potential
to overcome the limitations of traditional commercial manufacturing methods that do
not translate well to commercial production of advanced therapies due to their cost
prohibitive nature and complex logistics to deliver such treatments to patients (ultimately
limiting the number of patients that can have access to, or can afford, these therapies).

Additional info from OTC:
We are a global biotech company working to unlock the potential of cell and gene
therapies ("CGTs") in an affordable and accessible format. CGTs can be centered on
autologous (using the patients own cells) or allogenic (using master banked donor cells)
and are part of a class of medicines referred to as advanced therapy medicinal products
("ATMPs"). We are mostly focused on autologous therapies that can be manufactured
under processes and systems that are developed for each therapy using a closed and
automated approach that is validated for compliant production near the patient for
treatment of the patient at the point of care ("POCare"). This approach has the potential
to overcome the limitations of traditional commercial manufacturing methods that do
not translate well to commercial production of advanced therapies due to their cost
prohibitive nature and complex logistics to deliver such treatments to patients (ultimately
limiting the number of patients that can have access to, or can afford, these therapies).